CD20 / MS4A1 (B-Cell Marker)(L26 + IGEL/773), CF640R conjugate, 0.1mg/mL [26628-22-8]

Biotium

CD20 / MS4A1 (B-Cell Marker)(L26 + IGEL/773), CF640R conjugate, 0.1mg/mL

9

Research Use Only

Monoclonal

L26 IGEL/773

0.1 mg/ml

Other Conjugate

MS4A1

membrane spanning 4-domains A1

B1; B-lymphocyte antigen CD20; B-lymphocyte cell-surface antigen B1; Bp35; CD20; CD20 antigen; CD20 receptor; CVID5; FMC7; LEU-16; leukocyte surface antigen Leu-16; membrane-spanning 4-domains, subfamily A, member 1; S7

Mouse

IgG2a

B-lymphocyte antigen CD20

This antibody recognizes a protein of 30-33 kDa, which is identified as CD20. Its epitope is located in the cytoplasmic domain of CD20 and was, therefore, ascribed as CD20cy in the 5th Workshop. CD20 is a non-Ig differentiation antigen of B-cells and its expression is restricted to normal and neoplastic B-cells, being absent from all other leukocytes and tissues. CD20 is expressed by pre B-cells and persists during all stages of B-cell maturation but is lost upon terminal differentiation into plasma cells. This MAb can be used for immunophenotyping of leukemia and malignant cells, B lymphocyte detection in peripheral blood and B cell localization in tissues. It reacts with the majority of B-cells present in peripheral blood and lymphoid tissues and their derived lymphomas. In lymphoid tissue, germinal center blasts and B-immunoblasts are particularly reactive. It is a reliable antibody for ascribing a B-cell phenotype in known lymphoid tissues. Rarely, CD20-positive T-cell lymphomas have been reported. Reactivity has also been noted with Reed-Sternberg cells in cases of Hodgkin s disease, particularly of lymphocyte predominant type.

Animal

Bovine, Human, Monkey, Mouse, Primate

2°C to 8°C

12352203